Typhoid vaccine: Canadian Immunization Guide
For health professionals
Last complete chapter revision (see Table of Updates): April 2017
On this page
- Key Information
- Preparations Authorized for Use in Canada
- Immunogenicity, Efficacy and Effectiveness
- Recommendations for Use
- Vaccination of Specific Populations
- Vaccine Administration Practices
- Storage and Handling Requirements
- Safety and Adverse Events
- Selected References
Key Information (refer to text for details)
- Typhoid fever is caused by Salmonella enterica subspecies enterica serovar Typhi (S. typhi).
- S. typhi is generally transmitted through ingestion of food and water contaminated with the feces of people with the disease or who are chronic S. typhi carriers.
- Clinical course ranges from mild illness with low grade fever to severe systemic disease with abdominal perforation and extra-intestinal infection that, if untreated, may be fatal.
- There are 3 types of typhoid vaccines: parenteral (Typh-I), parenteral combined with hepatitis A (HA-Typh-I), and oral (Typh-O). These vaccines provide approximately 50% protection against clinical disease.
- Protection following Typh-I vaccine lasts for 3 years; protection following Typh-O vaccine lasts for about 7 years.
- The most commonly reported adverse events following immunization with Typh-I vaccine are injection site reactions (pain, swelling); the most commonly reported adverse events following receipt of Typh-O vaccine are abdominal pain, nausea, diarrhea, vomiting, fever, headache and rash.
- Typhoid immunization is recommended for most persons, 2 years of age and older, travelling to South Asia including Afghanistan, Bangladesh, Bhutan, India, Maldives, Nepal, Pakistan and Sri Lanka.
- Typhoid immunization is not routinely recommended for travel outside of South Asia; however, it might be considered for travellers to other areas, such as Africa, based on individual-specific risk factors and personal preference.
- Typhoid immunization is recommended for laboratory personnel at risk of exposure to S. typhi and for people in close contact with S. typhi carriers.
- A single 0.5 mL dose of Typh-I vaccine should be administered for people 2 years of age and older when indicated.
- A single 1.0 mL dose of HA-Typh-I vaccine should be administered for people 16 years of age and older when indicated.
- One capsule of Typh-O should be taken on alternate days to a total of 4 capsules of vaccine for people 5 years of age and older. Typh-O vaccine should be taken approximately 1 hour before, or 2 hours after a meal.
- Typh-O vaccine is contraindicated in individuals with an acute gastrointestinal condition or inflammatory bowel disease and in immunocompromised persons, including those with known HIV infection.
- Administration of oral cholera vaccine and Typh-O vaccine should be separated by at least 8 hours.
- Typh-O vaccine may be given concomitantly with or at any time before or after any parenteral vaccine.
- Typh-I vaccine and other travel vaccines may be given concomitantly.
- The World Health Organization (WHO) has estimated that there are 21 million cases of typhoid per year. About 2% to 5% of untreated typhoid cases become chronic carriers.
- The case fatality rate is approximately 10% for untreated cases in low income settings and less than 1% for patients receiving care in high income countries.
This chapter update was conducted in collaboration with the Committee to Advise on Tropical Medicine and Travel (CATMAT). Recommendations are based on CATMAT’s Statement on International Travellers and Typhoid.
Significant revisions included in this chapter are highlighted in the Table of Updates to the Canadian Immunization Guide.
Typhoid fever is caused by a bacterium, Salmonella enterica subspecies enterica serovar Typhi (S. typhi). It is a subset of the clinical syndrome known as “enteric fever”, caused by several Salmonella species. The clinical presentation is similar for all of these species; however the vaccine is only active against S.typhi. For additional information about Salmonella enterica, refer to the Pathogen Safety Datasheet.
S. typhi is generally transmitted through ingestion of food and water contaminated with the feces of people with the disease or those who are chronic S. typhi carriers. The incubation period is usually 8 to 14 days (range, 3 days to more than 60 days). Individuals infected with S. typhi are infectious as long as they are excreting the bacilli, usually from the first week of infection until symptoms have resolved. However, 10% of untreated individuals excrete the bacilli for 3 months or more after initially contracting the disease and 2% to 5% of untreated individuals become asymptomatic chronic carriers.
The overall risk of developing typhoid during travel to typhoid endemic countries is very low (less than 1 case per 100,000 travellers). The strongest and most consistent predictor of typhoid risk in travellers is destination of travel. The estimated risk of developing travel-associated typhoid is about: 1 in 3,000 travellers for travel to South Asia (high risk), 1 in 50,000 to 100,000 travellers for travel to Sub-Saharan Africa, North Africa, the Middle East and South America (intermediate risk), and less than 1 in 300,000 travellers for travel to the Caribbean, Central America and Eastern Mediterranean (low risk).
It is known that people with anatomic or functional asplenia (that is, from sickle cell disease) are at increased risk of severe disease from encapsulated bacteria. Several studies have identified travelling children, longer duration of travel, the presence of achlorhydria or use of acid suppression therapy, and travellers visiting friends or relatives, as factors that increase the risk of travel-associated typhoid. The incremental magnitude of risk that these factors contribute in addition to travel destination is unclear.
Although immunocompromised conditions, such as HIV infection, are recognized to predispose to more severe and complicated infections, in general they do not appear to be associated with an increased risk of S. typhi infection.
In Canada, chronic S. typhi carriers pose the greatest public health risk, particularly when they are working in the food industry.
Spectrum of clinical illness
Typhoid fever is a systemic illness of varying severity. The clinical course ranges from mild illness with low grade fever to severe systemic disease with abdominal perforation and extra-intestinal infection that, if untreated, may be fatal. Symptoms may include fever, headache, abdominal pain, nausea, vomiting, malaise, anorexia, bradycardia, splenomegaly, cough, rose spots on the trunk, and constipation. The case fatality rate is approximately 10% for untreated cases in low income settings and less than 1% for patients receiving care in high income countries. Between 2% and 5% of typhoid cases become chronic carriers, sometimes shedding bacteria in stool for years.
Incidence and prevalence
S. typhi infection continues to be a chief cause of enteric disease and remains a significant public health issue in low and middle income countries, principally among children. The WHO estimates the global incidence of typhoid fever to be 21 million cases per year, with 222,000 associated deaths annually. Globally, it is estimated that more than 90% of typhoid cases and deaths occur in Asian countries, predominantly in South Asia.
The incidence of typhoid fever in high income countries is low at <15 cases per 100,000 persons per year. The majority of cases of typhoid fever in these countries occur among travellers returning from endemic areas in low and middle income countries.
In Canada, where most cases of typhoid occur in travellers, there was a mean of 144 cases of typhoid reported annually (2004 to 2013), with a mean incidence rate of 0.43 per 100,000 population. In a recent study in Quebec, more than 90%of typhoid cases reported by international travellers were people who were travelling for the purpose of visiting family members or friends living abroad.
Preparations Authorized for Use in Canada
- TYPHIM Vi® (Salmonella typhi Vi capsular polysaccharide vaccine for injection), Sanofi Pasteur SA (manufacturer), Sanofi Pasteur Ltd. (distributor) (Typh-I)
- ViVAXIM® (combined purified Vi polysaccharide typhoid and inactivated hepatitis A vaccine for injection), Sanofi Pasteur SA (manufacturer), Sanofi Pasteur Ltd. (distributor) (HA-Typh-I)
- Vivotif® (live, oral, attenuated TY21A typhoid vaccine),PaxVax Berna GmbH. (manufacturer), Crucell Vaccines Inc. (distributor) (Typh-O)
There are no authorized vaccines to protect against S. paratyphi infection (paratyphoid).
For complete prescribing information, consult the product leaflet or information contained within the product monograph available through Health Canada’s Drug Product Database.
Refer to Contents of Immunizing Agents Available for Use in Canada in Part 1 for a list of vaccines available for use in Canada and their contents.
Immunogenicity, Efficacy and Effectiveness
Immunity following Typh-I vaccine is thought to last for 3 years. Equivalent seroconversion rates are achieved by HA-Typh-I vaccine compared with typhoid and monovalent HA vaccines.
Protective antibodies are detectable for about 7 years following receipt of Typh-O vaccine.
Efficacy and effectiveness
Efficacy of typhoid vaccine, both oral and intramuscular formulations, in preventing typhoid is approximately 50%. Evidence suggests that oral typhoid vaccine provides some protection against paratyphoid; however, the evidence is insufficient to recommend the off-label use of typhoid vaccine for this indication.
Recommendations for Use
Children (2 to 17 years of age) and adults (18 years of age and older)
Typh-I vaccine is indicated for persons 2 years of age and older and Typh-O vaccine may be used in people 5 years of age and older who are travelling to endemic areas. HA-Typh-I vaccine is indicated for those travellers who are 16 years of age and older and also require protection against hepatitis A.
Most Canadian travellers visiting South Asia (including Afghanistan, Bangladesh, Butan, India, Maldives, Maldives, Nepal, Pakistan and Sri Lanka) should be offered typhoid vaccine. The risk of typhoid is highest for persons travelling to India, Pakistan, and Bangladesh. Data suggest that most cases of typhoid occur when travellers stay more than 2 weeks.
The decision of whether to immunize a traveller for destinations other than South Asia (for example, Africa) should be carefully balanced against the presence of other factors that may increase the risk of travel-associated typhoid: travelling children; travellers visiting friends and relatives; longer duration of travel and prolonged exposure to potentially contaminated food and water; anatomic or functional asplenia (including sickle cell anemia), the presence of achlorhydria or the use of acid suppression therapy; and personal preference.
Immunization is only modestly effective against typhoid and provides no protection against other fecal-oral diseases; therefore, all travellers should be advised to adhere to basic sanitation and food and water precautions irrespective of whether they are immunized against typhoid.
Refer to Immunization of Travellers in Part 3 for additional information about typhoid vaccination of travellers.
Contacts of chronic carriers
Typhoid immunization is recommended for individuals with ongoing or intimate exposure (for example, family member) to a chronic carrier of S. typhi.
Table 1 provides a summary of typhoid vaccines available for use in Canada.
Persons 2 years of age and older for whom the vaccine is indicated should receive a single 0.5 mL dose intramuscularly at least 14 days prior to potential exposure.
Persons 5 years of age and older for whom the vaccine is indicated should take 1 capsule on alternate days to a total of 4 capsules. All 4 capsules must be taken for optimal protection. Minor variations in dosing schedule are not expected to affect efficacy. However, if it is necessary to repeat the series because of a longer interval between doses (more than 1 week), the administration of an additional full course of vaccine is not harmful. The capsules should be administered in accordance with the instructions in the manufacturer’s product leaflet. Immunization (i.e. ingestion of all 4 capsules) should be completed at least 7 days prior to potential exposure.
When both typhoid vaccine and hepatitis A vaccine are indicated, persons 16 years of age and older should receive a single 1.0 mL dose for primary immunization against these infections, and to protect against typhoid, at least 14 days prior to potential exposure. To provide long-term protection against hepatitis A, a booster dose of hepatitis A vaccine should be given 6 to 36 months later. Alternatively, HA-Typh-I vaccine can be given as a booster vaccine after 3 years in people who also require ongoing protection against typhoid. Refer to Hepatitis A Vaccine in Part 4 for additional information.
|Vaccines||Parenteral inactivated vaccines
|Oral, live attenuated vaccine
|Combined, parenteral inactivated vaccine (HA-Typh-I)|
|Authorized for use in persons||2 years of age and older||5 years of age and older||16 years of age and older|
|Protection begins||14 days following vaccination||7 days following vaccination||14 days following vaccination|
|Dose and schedule||1 dose: 0.5 mL||1 capsule taken on alternate days, total of 4 capsules||1 dose: 1.0 mL|
|Route of administration||Intramuscular injection||Oral||Intramuscular injection|
|Contraindications||Individuals with hypersensitivity or anaphylaxis to any component of the vaccine or its container.||
||Individuals with hypersensitivity or anaphylaxis to any component of the vaccine or its container.|
|Re-immunizationTable 1 footnote 2||Every 3 years||Every 7 yearsTable 1 footnote 3||
Refer to additional information contained within the product monographs available through Health Canada's Drug product database.
Booster doses and re-immunization
Periodic booster doses in persons at continued risk of typhoid may be expected to increase antibody titres and to maintain protection. Booster doses should be offered when a person remains at risk in conditions of repeated or continuous exposure. For Typh-I vaccine, a booster dose should be administered every 3 years. For Typh-O vaccine, a booster of 4 doses should be administered every 7 years. For the combined HA-Typh-I vaccine, a single dose of hepatitis A vaccine should be given 6 to 36 months later; a single dose of Typh-I vaccine may be given at or after 3 years; HA-Typh-I vaccine can be used after 3 years if boosters are needed for both hepatitis A and typhoid.
Typhoid immunization is not routinely recommended for the control or containment of typhoid outbreaks in Canada.
Vaccination of Specific Populations
Pregnancy and breastfeeding
No information is available on the safety of Typh-I vaccine in pregnancy; however, there is no theoretical reason to suspect an increased risk from inactivated vaccines, such as Typh-I vaccine. Typhoid vaccine should be considered in pregnant women, when indicated for travel to endemic areas, the presence of risk factors, and personal preference. Breastfeeding women may be given inactivated Typh-I vaccine.
Before immunization of pregnant women with Typh-O vaccine, the benefits of administration must be carefully weighed against potential adverse events. Typh-O vaccine should only be used in pregnancy when there is a high risk of infection and Typh-I vaccine is not available. It is not known if the live bacteria or any other component of Typh-O vaccine can pass into breast milk.
Refer to Immunization in Pregnancy and Breastfeeding in Part 3 for additional information about vaccination of women who are pregnant or breastfeeding.
Typh-I vaccine may be administered to immunocompromised persons if indicated; however, an adequate response may not be achieved. When considering immunization of an immunocompromised person with Typh-I vaccine, consultation with the individual's attending physician may be of assistance. For complex cases, referral to a physician with expertise in immunization or immunodeficiency is advised. Typh-O vaccine should not be given to immunocompromised persons, including those with known HIV infection.
Household contacts of immunocompromised persons may receive Typh-O vaccine; healthy persons vaccinated with Typh-O vaccine do not shed vaccine-strain organisms in their stool and secondary transmission to contacts does not occur.
Typhoid vaccine is recommended for laboratory personnel regularly working with S. typhi. Technicians working in routine microbiology laboratories do not need to be vaccinated with typhoid vaccine.
Refer to Immunization of Workers in Part 3 for additional information about vaccination of workers.
Vaccine Administration Practices
Each dose of Typh-I vaccines is 0.5 mL.
Each dose of HA-Typh-I vaccine is 1.0 mL.
Each dose of Typh-O vaccine is 1 capsule.
Route of administration
Typh-I and Ha-Typh-I vaccines should be administered intramuscularly. Typh-O vaccine should be administered orally; it can be self-administered.
Refer to Vaccine Administration Practices in Part 1 for additional information about pre-vaccination and post-vaccination counselling, vaccine preparation and administration technique, and infection prevention and control.
Interchangeability of vaccines
Although there are no data regarding the interchangeability of typhoid vaccines, it is presumed that boosting can be performed with any of the available formulations, regardless of the vaccine used initially. The boosting interval should correspond to the interval established for the preceding vaccine.
Refer to Principles of Vaccine Interchangeability in Part 1 for additional information about vaccine interchangeability.
Concurrent administration with other vaccines
The administration of oral cholera and travellers’ diarrhea vaccine and Typh-O vaccine capsules should be separated by at least 8 hours; Typh-O vaccine can be given concomitantly with or at any time before or after any parenteral vaccine. There is no known interaction between Typh-I vaccine and other travel vaccines, such as hepatitis A vaccine, yellow fever vaccine and hepatitis B vaccine.
Refer to Timing of Vaccine Administration in Part 1 for additional information about concurrent administration of vaccines.
Serologic testing is not recommended before or after receiving typhoid vaccine.
Storage and Handling Requirements
Typhoid vaccines should be stored at +2°C to +8°C and should not be frozen. Typh-O vaccine should be protected from light, moisture and high humidity.
Refer to Storage and Handling of Immunizing Agents in Part 1 for additional information and recommendations.
Safety and Adverse Events
Common and local adverse events
Common adverse events (1% to 10% of vaccine recipients) include: injection site tenderness, induration, redness or pain, fever, headache, general malaise or myalgia.
Common adverse events include: abdominal pain, nausea, diarrhea, vomiting, fever, headache and rash.
Very common (more than 10% of vaccine recipients) adverse events include: injection site pain, induration, swelling and erythema; headache; myalgia and weakness. Common adverse events include: fever, malaise, nausea, diarrhea and dizziness. Uncommon adverse events (0.1% to less than 1% of vaccine recipients) include: pruritus and rash.
Less common and serious or severe adverse events
Serious adverse events are rare following immunization and, in most cases, data are insufficient to determine a causal association. Anaphylaxis following vaccination with typhoid vaccine is very rare.
Guidance on reporting Adverse Events Following Immunization (AEFI)
Vaccine providers are asked to report, through local public health officials, any serious or unexpected adverse event temporally related to vaccination. An unexpected AEFI is an event that is not listed in available product information but may be due to the immunization, or a change in the frequency of a known AEFI.
Refer to Reporting Adverse Events Following Immunization (AEFI) in Canada and Adverse events following immunization in Part 2 for additional information about AEFI reporting.
Contraindications and precautions
Typhoid vaccine is contraindicated in people with a history of anaphylaxis after previous administration of the vaccine and in people with proven immediate or anaphylactic hypersensitivity to any component of the vaccine or its container.
Refer to Contents of Immunizing Agents Available for Use in Canada in Part 1 for a list of vaccines available for use in Canada and their contents.
Typh-O vaccine is contraindicated in individuals with an acute gastrointestinal condition or inflammatory bowel disease and in immunocompromised persons.
Administration of typhoid vaccine should be postponed in persons with severe acute illness. Persons with minor acute illness (with or without fever) may be vaccinated.
Refer to Contraindications, Precautions and Concerns in Part 2 for additional information. Refer to Pregnancy and Breastfeeding for additional information about vaccination of women who are pregnant or breastfeeding.
Drug-drug and drug-food interactions
The Typh-O vaccine series should be finished 3 days before commencing, or initiated 48 to 72 hours after completing, treatment with sulphonamides or other antibiotics active against S. typhi, or antimalarials. Exceptions include chloroquine, mefloquine and atovaquone/proguanil (Malarone®), as these antimalarials do not affect the immune response to Typh-O vaccine and can be administered at the same time as, or at any interval before or after Typh-O vaccine.
Typh-O vaccine should be taken approximately 1 hour before, or 2 hours after a meal. Alcoholic beverages should not be consumed 1 hour before or 2 hours after taking Typh-O vaccine.
Typh-I, HA-Typh-I or Typh-O vaccines can be given before, concurrently with, or after immunoglobulin or other blood products.
- American Public Health Association. Control of Communicable Diseases Manual. 19th ed. Washington; 2008.
- Basnyat B, Maskey AP, Zimmerman MD et al. Enteric (typhoid) fever in travelers. Clin Infect Dis 2005 Nov 15;41(10):1467-72.
- Beeching NJ, Clarke PD, Kitchin NR et al. Comparison of two combined vaccines against typhoid fever and hepatitis A in healthy adults. Vaccine 2004;23(1):29-35.
- Begier EM, Burwen DR, Haber P, Ball R, the Vaccine Adverse Event Reporting System Working Group. Postmarketing safety surveillance for typhoid fever vaccines from the Vaccine Adverse Event Reporting System, July 1990 through June 2002. Clin Infect Dis 2004;38(6):771-79.
- Bhutta ZA. Typhoid fever: current concepts. Infect Dis Clin Pract 2006 Sep;14(5):266-72.
- Bui YG, Trepanier S, Milord F et al. Cases of malaria, hepatitis A, and typhoid fever among VFRs, Quebec (Canada). J Travel Med 2011;18(6):373-8.
- Campbell JD, Levine MM. Typhoid and cholera vaccines. In: Jong EC, Zuckerman JN, eds. Travelers’ vaccines. Hamilton, Ontario: Decker Inc, 2004:162-84.
- Centers for Disease Control and Prevention. Health Information for International Travel 2016. The Yellow Book. Accessed January 2017. Available from: https://wwwnc.cdc.gov/travel/page/yellowbook-home-2014
- Chen LH, Wilson ME, Davis X et al. Illness in long-term travelers visiting GeoSentinel clinics. Emerg Infect Dis 2009 Nov;15(11):1773-82.
- Committee to Advise on Tropical Medicine and Travel (CATMAT). Statement on international travellers and typhoid. Can Commun Dis Rep 2014;40(4). Accessed April 2016 at: http://www.phac-aspc.gc.ca/publicat/ccdr-rmtc/14vol40/dr-rm40-04/dr-rm40-04-tropmed-eng.php
- Crump JA, Luby SP, Mintz ED. The global burden of typhoid fever. Bull World Health Organ 2004 May;82(5):346-53.
- Ekdahl K, de Jong B, Andersson Y. Risk of travel-associated typhoid and paratyphoid fevers in various regions. J Travel Med 2005;12(4):197-204.
- Fraser A, Goldberg E, Acosta CJ et al. Vaccines for preventing typhoid fever (Review). Cochrane Database Syst Rev 2007;3 CD001261.
- Keystone JS, Kozarsky PE, Freedman DO et al. Travel medicine. Elsevier, 2004.
- Lin FY, Ho VA, Khiem HB et al.The efficacy of a Salmonella typhi Vi conjugate vaccine in two-to-five year old children. N Engl J Med 2001;344(17):1263-69.
- Loebermann M, Kollaritsch H, Ziegler T. A randomized, open-label study of the immunogenicity and reactogenicity of three lots of a combined typhoid fever/hepatitis A vaccine in healthy adults. Clin Ther 2004;26(7):1084-91.
- Lynch MF, Blanton EM, Bulens S et al. Typhoid fever in the United States, 1999-2006. JAMA 2009 Aug 26;302(8):859-65.
- Parry CM, Hien TT, Dougan G et al. Typhoid fever. N Engl J Med 2002;347(22):1770-82.
- PaxVax Berna GmbH. Product Monograph - Vivotif®. January 2015.
- Public Health Agency of Canada. Notifiable Diseases On-Line. Accessed April 2016 at: http://dsol-smed.phac-aspc.gc.ca/dsol-smed/ndis/charts.php?c=yl
- Sanofi Pasteur SA. Product Monograph -VIVAXIM®. October 2015.
- Sanofi Pasteur Ltd. Product Monograph - TYPHIM Vi®. November 2013.
- Steinberg EB, Bishop R, Haber P et al. Typhoid fever in travelers: Who should be targeted for prevention? Clin Infect Dis 2004;39(2):186-91.
- World Health Organization. Immunization, Vaccines and Biologicals: Typhoid. Accessed April 2016. Available from: http://www.who.int/immunization/diseases/typhoid/en/
Report a problem or mistake on this page
- Date modified: